ALK and non-small cell lung carcinoma: Similarly, the ALINA trial evaluated patients with resected stage IB–IIIA (AJCC 7th edition) ALK-positive NSCLC randomized to receive either two years of alectinib or four cycles of platinum-based chemotherapy.